English 
Spanish 
TWiV 934 Clinical Update
This Week in Virology Host: Vincent Racaniello Guest: Daniel Griffin Aired 10 September 2022 pdf […]
TWiV 934 Clinical Update Read More »
TWiV 932 Clinical Update
This Week in Virology Host: Vincent Racaniello Guest: Daniel Griffin Aired 3 September 2022 pdf
TWiV 932 Clinical Update Read More »
September 22, 2022
Monkeypox in a Young Infant — Florida, 2022 | Health Care Personnel Exposures to Subsequently Laboratory-Confirmed Monkeypox Patients — Colorado, 2022 | Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022 | Association of COVID-19 with New-Onset Alzheimer’s Disease | Impact of mandatory vaccination of healthcare personnel on rates of influenza and other viral respiratory pathogens | Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak
September 22, 2022 Read More »
September 15, 2022
Severe Respiratory Illnesses Associated with Rhinoviruses and/or Enteroviruses Including EV-D68 – Multistate, 2022 | Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae | Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review | Effects of Vaccination and Previous Infection on Omicron Infections in Children | COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022 | Effectiveness of COVID-19 vaccines over time prior to Omicron emergence in Ontario, Canada
September 15, 2022 Read More »
September 08, 2022
Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19 | Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors | Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study | Variant Influenza Virus Infections: Recommendations for Identification, Treatment, and Prevention for Summer and Fall 2022 | Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
September 08, 2022 Read More »
Parasites Without Borders Raises $50,000 To Help Reopen FIMRC’s Project Bududa, Uganda Site
With a mission to bring healthcare resources to underserved communities, New York City-based global health nonprofit, Parasites Without Borders (PWB), raised $50,000 to help reopen the Foundation for International Medical Relief of Children’s (FIMRC) Project Bududa, Uganda site. Due to the pandemic, FIMRC had to stop in-person volunteer opportunities at their Bududa, Uganda site and therefore were lacking the necessary funds to continue operating the clinic.
TWiV 930 Clinical Update #129
This Week in Virology Host: Vincent Racaniello Guest: Daniel Griffin Aired 27 August 2022 pdf
TWiV 930 Clinical Update #129 Read More »
TWiV 926 Clinical Update #127
This Week in Virology Host: Vincent Racaniello Guest: Daniel Griffin Aired 13 August 2022 pdf
TWiV 926 Clinical Update #127 Read More »
September 1, 2022
Clinical Manifestations of Infection with Poliomyelitis Virus | Spike Protein-independent Attenuation of SARS-CoV-2 Omicron Variant in Laboratory Mice | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study | Distinguishing features of Long COVID identified through immune profiling | Unexplained post-acute infection syndromes | Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge | Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children
August 27, 2022
Clinical assessment of confirmed human monkeypox virus cases in Spain | Monkeypox Virus Infection across 16 Countries | Clinical characteristics of ambulatory and hospitalized patients with monkeypox | Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection | Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years | Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age | Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
